Trials / Completed
CompletedNCT06595004
A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients
A Randomized, Double-blind, Active-controlled, Non-inferiority, Multicenter Phase III Study to Evaluate the Efficacy and Safety of HCP1004 as Compared to RLD2401 in Chronic Low-Back Pain Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 310 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
A Randomized, Double-blind, Active-controlled, Non-inferiority, Multicenter Phase III Study to Evaluate the Efficacy and Safety of HCP1004 as compared to RLD2401 in Chronic Low-Back Pain Patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HCP1004 | Test Drug |
| DRUG | RLD2401 | Reference drug |
Timeline
- Start date
- 2024-11-22
- Primary completion
- 2025-06-18
- Completion
- 2025-06-18
- First posted
- 2024-09-19
- Last updated
- 2025-12-15
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06595004. Inclusion in this directory is not an endorsement.